APrf Robert Milne

APrf Robert Milne

School of Pharmacy and Biomedical Sciences

College of Health

Eligible to supervise Masters and PhD - email supervisor to discuss availability.

Welcome. I worked within the School of Pharmacy and Medical Sciences for many decades, but I have now retired from full-time employment. I have had many years of experience in teaching, research and consulting in pharmacy and pharmaceutical science. I have consulted widely to the pharmaceutical and biotechnology industry on pre-clinical and clinical studies, and worked closely with CPR Pharma, a spin-out company from UniSA. I have also provided scientific advice to patent firms on matters related to pharmaceutical science.
I now work part-time with the Drug Discovery and Development group, which is within the Centre for Cancer Diagnostics and Therapeutics. My contribution is research and supervision of doctoral students, supporting pre-clinical evaluation of the pharmacology of new anti-cancer drugs.

Drug discovery - preclinical development, pharmacokinetics and metabolism of drugs and their metabolites, drug analysis.

Year Citation
2026 Safaroghli-Azar, A., Mekonnen, L. B., Lenjisa, J., Milne, R., & Wang, S. (2026). Cell-cycle targeted cancer therapy: clinical advances, biological gaps, and the emergence of selective CDK4 inhibitors.. J Hematol Oncol, 19(1), 42 pages.
DOI
2025 Mekonnen, L. B., Teo, T., Noll, B., Rahaman, M. H., Lenjisa, J., Basnet, S., . . . Wang, S. (2025). A brain-penetrant CDK4/6 inhibitor - AU3-14 shows robust anti-tumor efficacy against glioblastoma.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 189(118340), 118340.
DOI Scopus6 Europe PMC5
2022 Anshabo, A. T., Bantie, L., Diab, S., Lenjisa, J., Kebede, A., Long, Y., . . . Wang, S. (2022). An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia. Cancers, 14(5), 1113.
DOI Scopus15 WoS12 Europe PMC10
2022 Wang, W., Joyce, P., Bremmell, K., Milne, R., & Prestidge, C. A. (2022). Liposomal 5-fluorouracil polymer complexes facilitate tumor-specific delivery: pharmaco-distribution kinetics using microdialysis. Pharmaceutics, 14(2, article no. 221), 1-16.
DOI Scopus12 WoS11 Europe PMC8
2021 Yu, M., Teo, T., Yang, Y., Li, M., Long, Y., Philip, S., . . . Wang, S. (2021). Potent and orally bioavailable CDK8 inhibitors: design, synthesis, structure-activity relationship analysis and biological evaluation. European Journal of Medicinal Chemistry, 214, 1-22.
DOI Scopus17 WoS15 Europe PMC15
2021 Bantie, L., Tadesse, S., Likisa, J., Yu, M., Noll, B., Heinemann, G., . . . Wang, S. (2021). Erratum to “A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer” (Gynecologic Oncology (2020) 159(3) (827–838), (S0090825820339056), (10.1016/j.ygyno.2020.09.012)). Gynecologic Oncology, 163(1), 215.
DOI
2021 Anshabo, A. T., Milne, R., Wang, S., & Albrecht, H. (2021). CDK9: A comprehensive review of its biology, and its role as a potential target for anti-cancer agents. Frontiers in Oncology, 11(678559), 1-24.
DOI Scopus130 WoS126 Europe PMC128
2020 Bantie, L., Tadesse, S., Likisa, J., Yu, M., Noll, B., Heinemann, G., . . . Wang, S. (2020). A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer.. Gynecol Oncol, 159(3), 827-838.
DOI Scopus17 WoS21 Europe PMC16
2020 Ellis, D. P., Rozek, T., & Milne, R. W. (2020). Stability of a compounded oral liquid formulation of clopidogrel for infants. Journal of Pharmacy Practice and Research, 50(4), 321-328.
DOI Scopus4
2019 Rahaman, M. H., Yu, Y., Zhong, L., Adams, J., Lam, F., Li, P., . . . Wang, S. (2019). CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia. Investigational new drugs, 37(4), 625-635.
DOI Scopus38 WoS38 Europe PMC30
2019 Abdelaziz, A. M., Diab, S., Islam, S., KC Basnet, S., Noll, B., Li, P., . . . Wang, S. (2019). Discovery of n-phenyl-4-(1h-pyrrol-3-yl)pyrimidin-2-amine derivatives as potent mnk2 inhibitors: design, synthesis, sar analysis, and evaluation of in vitro anti-leukaemic activity. Medicinal chemistry, 15(6), 600-621.
DOI Scopus6 WoS5 Europe PMC5
2019 Rahaman, M. H., Lam, F., Zhong, L., Teo, T., Adams, J., Yu, M., . . . Wang, S. (2019). Targeting CDK9 for treatment of colorectal cancer. Molecular Oncology, 13(10), 16 pages.
DOI Scopus48 WoS47 Europe PMC45
2019 Lee, K. J., Tieu, W., Blanco-Rodriguez, B., Paparella, A. S., Yu, J., Hayes, A., . . . Abell, A. D. (2019). Sulfonamide-based inhibitors of biotin protein ligase as new antibiotic leads. ACS Chemical Biology, 14(9), 1990-1997.
DOI Scopus9 WoS8 Europe PMC6
2019 Khair, N. Z., Lenjisa, J. L., Tadesse, S., Kumarasiri, M., Basnet, S. K. C., Mekonnen, L. B., . . . Wang, S. (2019). Discovery of CDK5 inhibitors through structure-guided approach. ACS, 10(5), 786-791.
DOI Scopus23 WoS22 Europe PMC21
2019 Hansen, B. D., Dahlhaus, P. G., Milne, R. G., MacLeod, A. D., & Pitfield, C. (2019). The Natural Resource Management Planning Portal: Perspectives for NRM Planning and Reporting. SOCIETY & NATURAL RESOURCES, 32(6), 709-719.
DOI
2018 Tadesse, S., Bantie, L., Tomusange, K., Yu, M., Islam, S., Bykovska, N., . . . Wang, S. (2018). Discovery and pharmacological characterisation of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents. British journal of pharmacology, 175(12), 2399-2413.
DOI Scopus25 WoS23 Europe PMC21
2018 Licari, G., Milne, R., Somogyi, A., & Sallustio, B. (2018). Enantioselectivity in the tissue distribution of perhexiline contributes to different effects on hepatic histology and peripheral neural function in rats. Pharmacology Research and Perspectives, 6(3), e00406.
DOI Scopus3 WoS3 Europe PMC3
2017 Tadesse, S., Yu, M., Mekonnen, L. B., Lam, F., Islam, S., Tomusange, K., . . . Wang, S. (2017). Highly potent, selective, and orally bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine cyclin-dependent kinases 4 and 6 inhibitors as anticancer drug candidates: design, synthesis, and evaluation. Journal of medicinal chemistry, 60(5), 1892-1915.
DOI Scopus75 WoS66 Europe PMC44
2017 Bai, P., Wittert, G., Taylor, A., Martin, S., Milne, R., Jenkins, A., . . . Shi, Z. (2017). The association between total phthalate concentration and non-communicable diseases and chronic inflammation in South Australian urban dwelling men. Environmental Research, 158, 366-372.
DOI Scopus44 WoS42 Europe PMC34
2017 Diab, S., Abdelaziz, A. M., Li, P., Teo, T., Basnet, S. K. C., Noll, B., . . . Wang, S. (2017). Dual inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia. European journal of medicinal chemistry, 139, 762-772.
DOI Scopus25 WoS23 Europe PMC19
2017 Lenjisa, J. L., Tadesse, S., Khair, N. Z., Kumarasiri, M., Yu, M., Albrecht, H., . . . Wang, S. (2017). CDK5 in oncology: recent advances and future prospects.. Future medicinal chemistry, 9(16), 1939-1962.
DOI Scopus40 WoS37 Europe PMC35
2017 Turkanovic, J., Ward, M. B., Gerber, J. P., & Milne, R. W. (2017). Effect of garlic, gingko, and St. John's wort extracts on the pharmacokinetics of fexofenadine: a mechanistic study. Drug metabolism and disposition, 45(5), 569-575.
DOI Scopus10 WoS7 Europe PMC7
2016 Diab, S., Li, P., Basnet, S. K. C., Lu, J., Yu, M., Albrecht, H., . . . Wang, S. (2016). Unveiling new chemical scaffolds as Mnk inhibitors. Future Medicinal Chemistry, 8(3), 271-285.
DOI Scopus22 WoS20 Europe PMC17
2016 Li, P., Diab, S., Yu, M., Adams, J., Islam, S., Basnet, S. K. C., . . . Wang, S. (2016). Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells. Oncotarget, 7(35), 1-15.
DOI Scopus24 WoS23 Europe PMC22
2016 Rahaman, M. H., Kumarasiri, M., Mekonnen, L. B., Yu, M., Diab, S., Albrecht, H., . . . Wang, S. (2016). Targeting CDK9: A promising therapeutic opportunity in prostate cancer. Endocrine Related Cancer, 23(12), T211-T226.
DOI Scopus64 WoS59 Europe PMC57
2015 Licari, G., Somogyi, A., Milne, R., & Sallustio, B. (2015). Comparison of CYP2D metabolism and hepatotoxicity of the myocardial metabolic agent perhexiline in Sprague-Dawley and Dark Agouti rats. Xenobiotica, 45(1), 3-9.
DOI Scopus3 WoS3 Europe PMC1
2015 Bai, P., Wittert, G., Taylor, A., Martin, S., Milne, R., & Shi, Z. (2015). The association of socio-demographic status, lifestyle factors and dietary patterns with total urinary phthalates in Australian men. PLoS One, 10(4), e01221400-1-e01221400-13.
DOI Scopus32 WoS30 Europe PMC26
2015 Le, B. T., Kumarasiri, M., Adams, J. R. J., Yu, M., Milne, R. W., Sykes, M. J., & Wang, S. (2015). Targeting Pim kinases for cancer treatment : opportunities and challenges. Future medicinal chemistry, 7(1), 35-53.
DOI Scopus47 WoS47 Europe PMC37
2014 Grant, J., Martin, S., Taylor, A., Wilson, D., Araujo, A., Adams, R., . . . Wittert, G. (2014). Cohort profile: The men androgen inflammation lifestyle environment and stress (MAILES) study. International Journal of Epidemiology, 43(4), 1040-1053.
DOI Scopus60 WoS55 Europe PMC51
2014 Lu, T., Goh, A. W., Yu, M., Adams, J., Lam, F., Teo, T., . . . Wang, S. (2014). Discovery of (E)-3-((Styrylsulfonyl) methyl) pyridine and (E)-2-((Styrylsulfonyl) methyl) pyridine Derivatives as Anticancer Agents: Synthesis, Structure–Activity Relationships, and Biological Activities. Journal of Medicinal Chemistry, 57(6), 2275-2291.
DOI Scopus37 WoS36 Europe PMC18
2014 Diab, S., Teo, T. H. S., Kumarasiri, M., Li, P., Yu, M., Lam, F., . . . Wang, S. (2014). Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors : synthesis, SAR analysis and biological evaluation. ChemMedChem, 9(5), 962-972.
DOI Scopus81 WoS77 Europe PMC59
2014 Diab, S., Kumarasiri, M., Yu, M., Teo, T., Proud, C., Milne, R., & Wang, S. (2014). MAP kinase-interacting kinases - emerging targets against cancer. Chemistry & Biology, 21(4), 441-452.
DOI Scopus92 WoS87 Europe PMC70
2012 Mihaila, B., Ellis, D., Rozek, T., & Milne, R. (2012). Chiral stability study of oral liquid clopidogrel formulations for infants. Journal of pharmacy practice and research, 42(2), 106-110.
DOI Scopus3
2011 Death, C., Taggart, D., Williams, D., Milne, R., Schultz, D., Holyoake, C., & Warren, K. (2011). Pharmacokinetics of moxidectin in the Southern hairy-nosed wombat (Lasiorhinus latifrons). Journal of Wildlife Diseases, 47(3), 643-649.
DOI Scopus21 WoS20 Europe PMC12
2011 Wiese, M. D., Davies, N. W., Chataway, T. K., Milne, R. W., Brown, S. G. A., & Heddle, R. J. (2011). Stability of Myrmecia pilosula (Jack Jumper) ant venom for use in immunotherapy. Journal of pharmaceutical and biomedical analysis, 54(2), 303-310.
DOI Scopus13 WoS13 Europe PMC11
2010 Dudhani, R., Turnidge, J., Coulthard, K., Milne, R., Rayner, C., Li, J., & Nation, R. (2010). Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrobial Agents and Chemotherapy, 54(3), 1117-1124.
DOI Scopus177 WoS172 Europe PMC143
2010 Qi, X., Evans, A. M., Wang, J., Miners, J. O., Upton, R. N., & Milne, R. W. (2010). Inhibition of morphine metabolism by ketamine. Drug metabolism and disposition, 38(5), 728-731.
DOI Scopus30 WoS25 Europe PMC22
2010 Lickliter, J. D., Francesconi, A. B., Smith, G., Burge, M., Coulthard, A., Rose, S., . . . Vasey, P. A. (2010). Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent. British Journal of Cancer, 103(5), 597-606.
DOI Scopus31 WoS27 Europe PMC21
2009 Turkanovic, J., Ngo, S., & Milne, R. (2009). Effect of St John's wort on the disposition of fexofenadine in the isolated perfused rat liver. Journal of Pharmacy and Pharmacology, 61(8), 1037-1042.
DOI Scopus5 WoS4 Europe PMC4
2009 Ma, Z., Wang, J., Nation, R., Li, J., Turnidge, J., Coulthard, K., & Milne, R. (2009). Renal Disposition of Colistin in the Isolated Perfused Rat Kidney. Antimicrobial Agents and Chemotherapy, 53(7), 2857-2864.
DOI Scopus80 WoS76 Europe PMC65
2008 Wallace, S., Li, J., Nation, R., Rayner, C., Taylor, D., Middleton, D., . . . Turnidge, J. (2008). Subacute toxicity of colistin methanesulfonate in rats: Comparison of various intravenous dosage regimens. Antimicrobial Agents and Chemotherapy, 52(3), 1159-1161.
DOI Scopus71 WoS72 Europe PMC61
2008 Davies, B., Herbert, M., Coller, J., Somogyi, A., Milne, R., & Sallustio, B. (2008). Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline. British Journal of Clinical Pharmacology, 65(3), 347-354.
DOI Scopus8 WoS8 Europe PMC6
2008 Bergen, P., Li, J., Nation, R., Turnidge, J., Coulthard, K., & Milne, R. (2008). Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Journal of Antimicrobial Chemotherapy, 61(3), 636-642.
DOI Scopus130 WoS118 Europe PMC104
2008 Wiese, M. D., Milne, R. W., Davies, N., Chataway, T., Brown, S., & Heddle, R. (2008). Myrmecia pilosula (Jack Jumper) ant venom: validation of a procedure to standardise an allergy vaccine. Journal of pharmaceutical and biomedical analysis, 46(1), 58-65.
DOI Scopus17 WoS15 Europe PMC13
2008 Ma, Z., Wang, J., Gerber, J. P., & Milne, R. W. (2008). Determination of colistin in human plasma, urine and other biological samples using LC-MS/MS. Journal of chromatography B: analytical technologies in the biomedical and life sciences, 862(1/2), 205-212.
DOI Scopus65 WoS62 Europe PMC48
2007 Inglis, S., Herbert, M., Davies, B., Coller, J., James, H., Horowitz, J., . . . Sallustio, B. (2007). Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia. Pharmacogenetics and Genomics (Print Edition), 17(5), 305-312.
DOI Scopus8 WoS7 Europe PMC5
2007 Davies, B., Coller, J., Somogyi, A., Milne, R., & Sallustio, B. (2007). CYP2B6 CYP2D6 and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. Drug Metabolism and Disposition, 35(1), 128-138.
DOI Scopus25 WoS23 Europe PMC21
2007 Wiese, M. D., Brown, S., Chataway, T., Davies, N., Milne, R. W., Aulfrey, S., & Heddle, R. (2007). Myrmecia pilosula (Jack Jumper) ant venom : identification of allergens and revised nomenclature. Allergy: European journal of allergy and immunology, 62(4), 437-443.
DOI Scopus43 WoS42 Europe PMC35
2007 Bazargan, M., Gerber, J. P., Wang, J., Chitsaz, M., Milne, R. W., & Evans, A. M. (2007). Determination of isosteviol by LC-MS/MS and its application for evaluation of pharmacokinetics of isosteviol in rat. DARU, 15(3), 146-150.
Scopus5 WoS5
2007 Mclachlan, A., Ramzan, I., & Milne, R. W. (2007). Frequently asked questions about generic medicines. Australian prescriber, 30(2), 41-43.
DOI Scopus17 WoS14
2007 Ma, J., Ma, Z., Wang, J., Milne, R. W., Xu, D., Davey, A. K., & Evans, A. M. (2007). Isosteviol reduces plasma glucose levels in the intravenous glucose tolerance test in Zucker diabetic fatty rats. Diabetes, obesity and metabolism, 9(4), 597-599.
DOI Scopus62 WoS58 Europe PMC34
2006 Bain, M., Faull, R., Milne, R., & Evans, A. (2006). Oral L-carnitine: Metabolite formation and hemodialysis. Current Drug Metabolism, 7(7), 811-816.
DOI Scopus27 WoS21 Europe PMC18
2006 Davies, B., Herbert, M., Coller, J., Somogyi, A., Milne, R., & Sallustio, B. (2006). Determination of the 4-monohydroxy metabolites of perhexiline in human plasma, urine and liver microsomes by liquid chromatography. Journal of Chromatography. B, Analytical Techniques in the Biomedical and Life Sciences, 843(2), 302-309.
DOI Scopus10 WoS10 Europe PMC5
2006 Li, J., Nation, R., Turnidge, J., Milne, R., Coulthard, K., Rayner, C., & Paterson, D. (2006). Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. The Lancet Infectious Diseases, 6(9), 589-601.
DOI Scopus1259 WoS1180 Europe PMC1022
2006 Bain, M., Faull, R., Fornasini, G., Milne, R., & Evans, A. (2006). Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis. Nephrology Dialysis Transplantation, 21(5), 1300-1304.
DOI Scopus256 WoS238 Europe PMC207
2006 Davies, B., Herbert, M., Culbert, J., Pyke, S., Coller, J., Somogyi, A., . . . Sallustio, B. (2006). Enantioselective assay for the determination of perhexiline enantiomers in human plasma by liquid chromatography. Journal of Chromatography. B, Analytical Techniques in the Biomedical and Life Sciences, 832(1), 114-120.
DOI Scopus17 WoS15 Europe PMC11
2006 Wiese, M. D., Chataway, T., Davies, N., Milne, R. W., Brown, S., Gai, W. P., & Heddle, R. (2006). Proteomic analysis of myrmecia pilosula (jack jumper) ant venom. Toxicon, 47(2), 208-217.
DOI Scopus36 WoS35 Europe PMC32
2006 Bain, M. A., Milne, R. W., & Evans, A. M. (2006). Disposition and metabolite kinetics of oral L-carnitine in humans. The Journal of Clinical Pharmacology, 46(10), 1163-1170.
DOI Scopus41 WoS38 Europe PMC27
2006 Shackleford, D. M., Evans, A. M., Milne, R. W., & Nation, R. (2006). Loading-washout studies of the stereoselective sinusoidal uptake of (R)-and (S)-2 phenylpropionyl acyl glucuronide. Current drug metabolism, 7(7), 817-826.
DOI
2005 Li, J., Nation, R., Milne, R., Turnidge, J., & Coulthard, K. (2005). Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. International Journal of Antimicrobial Agents, 25(1), 11-25.
DOI Scopus524 WoS481 Europe PMC402
2004 Li, J., Milne, R., Nation, R., Turnidge, J., Smeaton, T., & Coulthard, K. (2004). Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. Journal of Antimicrobial Chemotherapy, 53(5), 837-840.
DOI Scopus165 WoS152 Europe PMC134
2004 Bain, M. A., Faull, R., Fornasini, G., Milne, R. W., Schumann, R. C., & Evans, A. M. (2004). Quantifying trimethylamine and trimethylamine-N-oxide in human plasma: interference from endogenous quaternary ammonium compounds. Analytical biochemistry, 334(2), 403-405.
DOI Scopus26 WoS24 Europe PMC23
2004 Jensen, L. S., Valentine, J., Milne, R. W., & Evans, A. M. (2004). The quantification of paracetamol, paracetamol glucuronide and paracetamol sulphate in plasma and urine using a single high-performance liquid chromatography assay. Journal of Pharmaceutical and Biomedical Analysis, 34(3), 585-593.
DOI Scopus100 WoS88 Europe PMC42
2004 Milne, D., Foo, J. H. M., Sharley, N., & Milne, R. W. (2004). Phenytoin infusion revisited: stability and administration. Journal of Pharmacy Practice and Research, 34(4), 272-275.
DOI Scopus2
2004 Shackleford, D. M., Nation, R., Milne, R. W., Hayball, P. J., & Evans, A. M. (2004). Stereoselective hepatic disposition of model diastereomeric acyl glucuronides. Journal of Pharmacokinetics and Pharmacodynamics, 31(1), 1-27.
DOI Scopus5 WoS5 Europe PMC3
2003 Li, J., Milne, R., Nation, R., Turnidge, J., & Coulthard, K. (2003). Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high performance liquid chromatography. Antimicrobial Agents and Chemotherapy, 47(4), 1364-1370.
DOI Scopus198 WoS190 Europe PMC152
2003 Li, J., Coulthard, K., Milne, R., Nation, R., Conway, S., Peckham, D., . . . Turnidge, J. (2003). Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. Journal of Antimicrobial Chemotherapy, 52(6), 987-992.
DOI Scopus174 WoS162 Europe PMC142
2003 Li, J., Milne, R., Nation, R., Turnidge, J., Smeaton, T., & Coulthard, K. (2003). Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrobial Agents and Chemotherapy, 47(5), 1766-1770.
DOI Scopus159 WoS152 Europe PMC138
2003 Upton, R., Ludbrook, G., Martinez, A., Grant, C., & Milne, R. (2003). Cerebral and lung kinetics of morphine in conscious sheep after short intravenous infusions. British Journal of Anaesthesia, 90(6), 750-758.
DOI Scopus17 WoS17 Europe PMC13
2003 Karpf, D. M., Kirkegaard, A. L., Evans, A. M., Nation, R., Hayball, P. J., & Milne, R. W. (2003). Effect of ketoprofen and its enantiomers on the renal disposition of methotrexate in the isolated perfused rat kidney. Journal of pharmacy and pharmacology, 55(12), 1641-1646.
DOI Scopus7 WoS4 Europe PMC5
2003 Lucas, A. N., Brogan, L. R., Nation, R., Evans, A. M., & Shackleford, D. (2003). The effects of the phytoestrogenic isoflavone genistein on the hepatic disposition of preformed and hepatically-generated gemfibrozil-1-O-acyl glucuronide in the isolated perfused rat liver. Journal of pharmacy and pharmacology, 55(10), 1433-1439.
DOI Scopus2 WoS1
2003 Lucas, A. N., Nation, R., Milne, R. W., Reynolds, G. D., & Evans, A. M. (2003). The effects of phytoestrogenic isoflavones on the formation and disposition of paracetamol sulfate in the isolated perfused rat liver. Journal of pharmacy and pharmacology.
DOI
2003 Lucas, A. N., Nation, R. L., Milne, R. W., Reynolds, G. D., & Evans, A. M. (2003). The effects of phytoestrogenic isoflavones on the formation and disposition of paracetamol sulfate in the isolated perfused rat liver. Journal of Pharmacy and Pharmacology, 55(5), 639-646.
DOI Scopus5 WoS4 Europe PMC5
2002 Li, J., Milne, R., Nation, R., Turnidge, J., Coulthard, K., & Valentine, J. (2002). Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrobial Agents and Chemotherapy, 46(10), 3304-3307.
DOI Scopus103 WoS95 Europe PMC80
2001 Li, J., Milne, R., Nation, R., Turnidge, J., Coulthard, K., & Johnson, D. (2001). A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. Journal of Chromatography. B, Analytical Techniques in the Biomedical and Life Sciences, 761(2), 167-175.
DOI Scopus142 WoS135 Europe PMC104
2001 Shackleford, D. M., Hayball, P. J., Reynolds, G. D., Hamon, D., Evans, A. M., Milne, R. W., & Nation, R. L. (2001). A Small-Scale Synthesis and Enantiomeric Resolution of (RS)-[1-14C]-2-Phenylpropionic Acid and Biosynthesis of Its Diastereomeric Acyl Glucuronides. Journal of labelled compounds and radiopharmaceuticals, 44(3), 225-234.
DOI Scopus10 WoS9
2000 Milne, R. W., LarsenLA., Jorgensen, K. L., Bastlund, J. F., Stretch, G. L., & Evans, A. M. (2000). Hepatic disposition of fexofenadine: influence of the transport inhibitors erythromycin and dibromosulphothalein.. Pharmaceutical research, 17(12), 1511-1515.
DOI Scopus38 WoS29 Europe PMC20
1999 Stretch, G. L., Nation, R. L., Evans, A. M., & Milne, R. W. (1999). Organ perfusion techniques in drug development. Drug Development Research, 46(3-4), 292-301.
DOI Scopus13 WoS9
1997 Milne, R., McLean, C., Mather, L., Nation, R., Runciman, W., Rutten, A., & Somogyi, A. (1997). Influence of renal failure on the disposition of morphine, morphine-3-glucuronide and morphine-6-glucuronide in sheep during intravenous infusion with morphine. Journal of Pharmacology and Experimental Therapeutics, 282(2), 779-786.
DOI Scopus25 WoS21 Europe PMC14
1997 Milne, R. W., Jensen, R. H., Larsen, C., Evans, A. M., & Nation, R. L. (1997). Comparison of the disposition of hepatically-generated morphine-3-glucuronide and morphine-6-glucuronide in isolated perfused liver from the guinea pig. Pharmaceutical Research, 14(8), 1014-1018.
DOI Scopus17 WoS14 Europe PMC9
1996 Milne, R., Nation, R., & Somogyi, A. (1996). The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine.. Drug Metabolism Reviews, 28(3), 345-472.
DOI Scopus200 WoS181 Europe PMC135
1995 Milne, R., McLean, C., Mather, L., Nation, R., Runciman, W., Rutten, A., & Somogyi, A. (1995). Comparative disposition of morphine-3-glucuronide during separate intravenous infusions of morphine and morphine-3-glucuronide in sheep: Importance of the kidney. Drug Metabolism and Disposition, 23(3), 334-342.
DOI Scopus10 WoS8 Europe PMC4
1993 Milne, R. W., Sloan, P. A., McLean, C. F., Mather, L. E., Nation, R. L., Runciman, W. B., . . . Somogyi, A. A. (1993). Disposition of morphine and its 3- and 6-glucuronide metabolites during morphine infusion in the sheep. Drug metabolism and disposition, 21(6), 1151-1156.
DOI Scopus23 WoS21 Europe PMC14
1993 Somogyi, A. A., Nation, R. L., Olweny, C., Tsirgiotis, P., van Crugten, J., Milne, R. W., . . . Bochner, F. (1993). Plasma Concentrations and Renal Clearance of Morphine, Morphine-3-Glucuronide and Morphine-6-Glucuronide in Cancer Patients Receiving Morphine. Clinical Pharmacokinetics, 24(5), 413-420.
DOI Scopus48 WoS48 Europe PMC35
1992 Milne, R. W., Nation, R. L., Somogyi, A. A., Bochner, F., & Griggs, W. M. (1992). The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive-care patients. British Journal of Clinical Pharmacology, 34(1), 53-59.
DOI Scopus81 WoS72 Europe PMC54
1991 Sloan, P. A., Mather, L. E., Mclean, C. F., Rutten, A. J., Nation, R. L., Milne, R. W., . . . Somogyi, A. A. (1991). Physiological disposition of I.V. morphine in sheep. British Journal of Anaesthesia, 67(4), 378-386.
DOI Scopus26 WoS26 Europe PMC9
1991 Milne, R. W., Nation, R. L., Reynolds, G. D., Somogyi, A. A., & van Crugten, J. T. (1991). High-performance liquid chromatographic determination of morphine and its 3- and 6-glucuronide metabolites: improvements to the method and application to stability studies.. Journal of Chromatography B: Biomedical Applications, 565(1-2), 457-464.
DOI Scopus94 WoS88 Europe PMC45
1990 Nation, R. L., Evans, A. M., & Milne, R. W. (1990). Pharmacokinetic drug interactions with phenytoin (part II). Clinical pharmacokinetics, 18(2), 131-150.
DOI Scopus55 WoS52 Europe PMC29
1990 Nation, R. L., Evans, A. M., & Milne, R. W. (1990). Pharmacokinetic drug interactions with phenytoin (Part 1). Clinical pharmacokinetics, 18(1), 37.
DOI Scopus131 WoS115 Europe PMC85
1988 Milne, R., Coulthard, K., Nation, R., Penna, A., Roberts, G., & Sansom, L. (1988). Lack of effect of erythromycin on the pharmacokinetics of single oral doses of phenytoin.. British Journal of Clinical Pharmacology, 26(3), 330-333.
DOI Scopus14 WoS13 Europe PMC10
1984 MILNE, R. G. (1984). UNIT MEDICAL OFFICER. NEW ZEALAND MEDICAL JOURNAL, 97(765), 703.
1980 Allen, N., Milne, R., & Sansom, L. N. (1980). Bioavailability of a sustained released theophylline product. Australian Journal of Pharmaceutical Sciences, 9(2), 50.
Scopus1
1979 Sansom, L. N., Milne, R. W., & Cooper, D. (1979). Comparative bioavailability of a microcrystalline theophylline tablet and uncoated aminophylline tablets. European journal of clinical pharmacology, 16(6), 417-421.
DOI Scopus5 WoS10 Europe PMC6
1976 MILNE, R. G. (1976). UNEMPLOYMENT IN MALTA, 1956-71. JOURNAL OF DEVELOPMENT STUDIES, 12(4), 383-395.
DOI

Year Citation
2007 Sallustio, B. C., Davies, B. J., Herbert, M. K., Coller, J. K., Somogyi, A. A., & Milne, R. W. (2007). Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 extensive and poor metabolisers. In THERAPEUTIC DRUG MONITORING Vol. 29 (pp. 478). Nice, FRANCE: LIPPINCOTT WILLIAMS & WILKINS.
2004 Kong, L., Gao, W., Evans, A. M., Wang, B., & Milne, R. W. (2004). Influence of geometrical design and flow conditions on the performance of a microatomiser. In Proceedings of ESDA 2004: 7th Biennial Conference on Engineering Systems Design and Analysis Vol. 3 (pp. 47-52). USA: American Society of Mechanical Engineers.
DOI
2001 Li, J., Turnidge, J., Milne, R., Nation, R., & Coulthard, K. (2001). In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. In Antimicrobial Agents and Chemotherapy Vol. 45 (pp. 781-785). United States: Amer Soc Microbiology.
DOI Scopus216 WoS200 Europe PMC173
2000 Shackleford, D. M., Evans, A. M., Hayball, P. J., Milne, R. W., & Nation, R. L. (2000). Stereoselective biliary excretion of the hepatically-generated acyl glycuronide metabolites of (R)- and (S)-2-phenylpropionic acid. In proceedings of the Millennial World Congree of Pharmaceutical Sciences.
2000 Li, J., Milne, R. W., Nation, R. L., Turnidge, J., Coulthard, K., & Johnson, D. (2000). A novel assay method for colistin in human plasma using pre-column derivatization with 9-fluroenylmethyl chloroformate for RP-HPLC. In Proceedings of the APSA 2000 Annual Conference.
2000 Lucas, A. N., Evans, A. M., Milne, R. W., & Nation, R. L. (2000). The effects of phytoestrogenic isoflavones on the hepatic disposition of paracetamol. In Proceedings of the APSA 2000 Annual Conference.
2000 Mojarrabi, B., Lucas, A. N., Beck, A. R., Evans, A. M., Milne, R. W., & Nation, R. L. (2000). Validation of a Caco-2 cell monolayer systenm to investigate transport via P-glycoprotein. In Proceedings of the APSA 2000 Annual Conference.
1999 Shackleford, D. M., Evans, A. M., Hayball, P. J., Milne, R. W., & Nation, R. L. (1999). Stereoselective excretion of the hepatically-generated acyl glucuronide metabolites of (R)-(-)-and (S)-(+)-2-phenylpropionic acid. In APSA.
1999 Stretch, G. L., Nation, R. L., Evans, A. M., Hayball, P. J., & Milne, R. W. (1999). Extensive tubular secretion of zidovudine and its ether-glucuronide in the isolated perfused rat kidney. In APSA.
1999 Milne, R. W., Jorgensen, K. L., Stretch, G. L., & Evans, A. M. (1999). Hepatic disposition of fexofenadine: the influence of perfusate concentration. In APSA.
1999 Khalil, V., Evans, A. M., Hayball, P. J., Milne, R. W., & Nation, R. L. (1999). Disposition of gemfibrozil and its acyl glucuronide in the isolated perfused rat kidney. In APSA.
1998 Ng, D., Evans, A. M., Milne, R. W., & Nation, R. L. (1998). The renal disposition of methotrexate in the isolated perfused rat kidney: concentration ranging and the influence of probenecid. In Proceedings of ASCEPT. Australia: ASCEPT.
1998 Milne, R. W., Evans, A. M., Nation, R. L., Shanahan, K. M., & Marwood, A. C. (1998). Disposition of morphine and its glucuronide metabolites in the isolated perfused liver of the guinea pig - concentration ranging studies. In Proceedings of the 5th International ISSX Meeting. USA: ISSX.
1998 Shackleford, D. M., Evans, A. M., Hayball, P. J., Milne, R. W., & Nation, R. L. (1998). Pharmacokinetics of 2-phenylpropionic acid enantiomers in the single-pass isolated perfused rat liver. In Proceedings of ASCEPT. AUSTRALIA: ASCEPT.
1998 Khalil, V., Evans, A. M., Hayball, P. J., Milne, R. W., Nation, R. L., Sallustio, B., & Stretch, G. L. (1998). Functional parameters of the isolated perfused kidney with dextran. In Proceedings of ASCEPT. Australia: ASCEPT.

  • Development of a novel and highly selective CDK4/6 inhibitor for treating cancer, NHMRC - Development Grant, 01/01/2018 - 30/04/2022

  • The inhibition of Biotin Protein Ligase as a new source of antibiotics, NHMRC - Project Grant, 01/01/2014 - 31/12/2017

  • Stability of liquid dosage forms of clopidgrel for paediatric use, Women's and Children's Hospital, 15/05/2014 - 30/09/2017

Date Role Research Topic Program Degree Type Student Load Student Name
2022 Co-Supervisor span class="cf0">Preclinical evaluation of a CDK4 inhibitor AU2-94 for the treatment of cancer Doctor of Philosophy Doctorate Full Time Miss Ava Safaroghliazar

Date Role Research Topic Program Degree Type Student Load Student Name
2021 - 2025 Co-Supervisor Preclinical evaluation of a novel CDK2 inhibitor as a potential cancer therapy Doctor of Philosophy Doctorate Full Time Dr Sara Kasirzadeh
2020 - 2024 Co-Supervisor Preclinical evaluation of TAM kinase inhibitors as potential anticancer agents Doctor of Philosophy Doctorate Full Time Dr Fatemeh Emadi
2018 - 2023 Co-Supervisor Design, synthesis, and evaluation of novel CDK2 inhibitors as potential anticancer agents Doctor of Philosophy Doctorate Full Time Mr Dessalegn Gelayee
2018 - 2022 Co-Supervisor Development of cyclin dependent kinase 9 inhibitors for the treatment of cancer Doctor of Philosophy Doctorate Full Time Mr Ramin Hassankhani Gharagozlou
2017 - 2020 Co-Supervisor Preclinical evaluation of novel dual CDK2/5 inhibitors as anticancer drug candidates Doctor of Philosophy Doctorate Full Time Mr Jimma Lenjisa
2017 - 2021 Co-Supervisor Pre-clinical Evaluation of FLT3 Inhibitors for Treatment of Acute Myeloid Leukaemia Doctor of Philosophy Doctorate Full Time Miss Jasmine Karanjia
2017 - 2021 Co-Supervisor Novel cyclin-dependent kinase 9 inhibitors for the treatment of cancer: identification and preclinical evaluation Doctor of Philosophy Doctorate Full Time Mr Abel Tesfaye Anshabo
2016 - 2020 Co-Supervisor Preclinical evaluation of inhibitors of cyclin-dependent kinases 4 and 6 for the treatment of cancer Doctor of Philosophy Doctorate Full Time Mr Laychiluh Mekonnen
2015 - 2019 Co-Supervisor Pre-clinical development of a CDK inhibitor for the treatment of cancer Doctor of Philosophy Doctorate Full Time Mr Muhammed Hamidur Rahaman
2013 - 2016 Co-Supervisor Developing inhibitorsof MAP kinase-interacting kinases as potential anti-cancer agents Doctor of Philosophy Doctorate Full Time Miss Sarah Al Haj Diab
2013 - 2019 Co-Supervisor Pharmacological evaluation of protein kinase inhibitors as anti-cancer agents Doctor of Philosophy Doctorate Part Time Ms Longjin Zhong
2009 - 2016 Principal Supervisor The impact of formulating 5-Fluorouracil into liposomes on its site-specific delivery to tumour tissue Doctor of Philosophy Doctorate Part Time Miss Wen Wang
2006 - 2016 Principal Supervisor Effect of garlic and ginkgo extracts on the pharmacokinetics of fexofenadine: a mechanistic study Doctor of Philosophy Doctorate Part Time Ms Jasmina Turkanovic
2005 - 2011 Co-Supervisor Pharmacokinetic interaction between morphine and ketamine Doctor of Philosophy Doctorate Full Time Miss Xiaoxin Qi
2005 - 2009 Co-Supervisor A pharmacokinetic study of 5-fluorouracil in tumour tissue using microdialysis Doctor of Philosophy Doctorate Full Time Ms Shuangjie Zhang
2005 - 2010 Co-Supervisor Renal disposition of colistin and colistin methanesulfonate in the isolated perfused rat kidney Doctor of Philosophy Doctorate Full Time Mr Zheng Ma
2003 - 2008 External Supervisor The Stereoselective Pharmacokinetics of the Enantiomers of Perhexiline in Poor and Extensive Metabolisers of the Cytochrome P450 2D6 Doctor of Philosophy Doctorate Full Time Mr Benjamin Davies
2002 - 2007 Principal Supervisor Characterisation of the allergic components and pharmaceutical development of Myrmecia pilosula (jack jumper) ant venom for immunotherapy Doctor of Philosophy Doctorate Part Time Mr Michael Wiese

Connect With Me

External Profiles

Other Links